Psychedelic Medicine & Rapid Mental Health

[DD+POD] Definium's single-dose LSD therapy DT120 posted its third straight Phase 3 win, cutting anxiety scores 9.8 points versus 4.7 for placebo in a 245-patient trial, with an FDA pre-NDA meeting planned this quarter and analysts putting approval odds above 90%.

[SCAN+TCR] FDA staff published a formal psychedelic-drug development framework in the New England Journal of Medicine covering existing breakthrough designations, including an LSD candidate for major depression.

[DD+POD] An NHS randomized trial of 60 adults found one 25-mg psilocybin dose produced 40% depression remission versus 3% on placebo, though participant blinding failed.

[DD+TCR] The first US psilocybin-assisted therapy trial for treatment-resistant veteran PTSD produced remission in 9 of 12 participants at one month with no serious adverse events.

[SCAN+TCR] Compass Pathways' COMP360 psilocybin held its antidepressant response through six months in a second Phase 3 trial for treatment-resistant depression, supporting a rolling FDA submission.

FDA issued national priority vouchers to Compass Pathways, Usona, and Transcend for psilocybin/methylone programs and cleared the first U.S. trial of an ibogaine-derivative for alcohol use disorder.

Trump executive order directed FDA to expedite breakthrough-therapy psychedelics, with 3 priority review vouchers expected next week, $50M federal research funding, right-to-try access pathways, and rapid post-Phase III rescheduling review.

No new developments in today's newsletter.

Nature publishes largest psychedelic neuroimaging meta-analysis (11 studies, 500+ scans, 267 people): psilocybin, LSD, DMT, mescaline, and ayahuasca all produce identical signature of enhanced brain network connectivity despite pharmacological differences: shared therapeutic mechanism identified.

Researchers engineered a single tobacco plant to simultaneously produce five psychedelics (psilocybin, DMT, 5-MeO-DMT, mescaline, bufotenine) by importing genes from mushrooms, toads, and cacti: biological manufacturing platform for complex psychoactive molecules demonstrated.

MIT Technology Review analysis documents psychedelics still falling short in clinical trials, with psilocybin depression results challenged by placebo effects: arc faces headwinds as clinical translation proves harder than early trial results suggested.

ACS/Journal of Medicinal Chemistry: modified psilocin derivatives activate serotonin pathways with significantly reduced hallucinogenic effects in mice: potential pathway to psychedelic-adjacent therapeutics without perceptual side effects.

Psilocybin durability data exceeds FDA request (26 weeks vs 12 requested).

DMT single dose (10-minute infusion): treatment-resistant depression lifted 2-6 months. 39% responders. Compass Pathways psilocybin Phase 3 met endpoint.